Drug makers question idea to shake up how Medicare pays for certain drugs

Stat News

24 April 2018 - Drug manufacturers are pushing back against one of the administration’s major proposals to bring down drug prices: a proposal to shift chemotherapy drugs and others administered in the hospital into a different part of Medicare.

The idea — which Health and Human Services Secretary Alex Azar first hinted at in his confirmation hearings and then proposed in the Trump administration’s fiscal year 2019 budget — would give insurance companies and pharmacy benefit managers new power to negotiate discounts on some of Medicare’s costliest drugs. 

That could mean big savings for the Medicare program itself, which might be passed on to consumers.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Medicare , Pricing